MedTrace Logo

Use of Tinzaparin for Anticoagulation in Hemodialysis

NCT01930396 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2016-10-14

No results posted yet for this study

Summary

The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Tinzaparin

DRUG

Unfractionated Heparin

DRUG

Placebo (for Tinzaparin)

0.9% Normal Saline

DRUG

Placebo (for Unfractionated Heparin)

0.9% Normal Saline

Sponsors & Collaborators

  • McMaster University

    collaborator OTHER

  • LEO Pharma

    collaborator INDUSTRY

  • Christine Ribic

    lead OTHER

Principal Investigators

  • Dr. Christine M Ribic, MD, MSc · St. Joseph's Healthcare Hamilton/McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01930396 on ClinicalTrials.gov